(PTPI) – Globe Newswire
-
NOTICE TO DISREGARD - Henry Crown and Company
-
Petros Pharmaceuticals Responds to Fraudulent Press Release
-
DELETED: Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share
-
Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky
-
Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US
-
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022
-
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology
-
Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)
-
Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights
-
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
-
Petros Pharmaceuticals to Participate in NobleCon17
Back to PTPI Stock Lookup
